IVVD — Invivyd, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1832038 ·
Last close
$0.77
Market Cap
$226.85M
52W High
$1.86
52W Low
$0.73
ADV30
3,810,547
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 13,744,000 | 12,712,000 | -43,136,000 | -41,400,000 | 241,742,000 | 184,153,000 | 38,692,000 |
| Dec 2025 | 17,207,000 | 16,067,000 | -12,555,000 | -11,070,000 | 276,883,000 | 226,689,000 | 35,343,000 |
| Sep 2025 | 13,129,000 | 12,041,000 | -11,023,000 | -10,470,000 | 139,158,000 | 84,967,000 | 46,090,000 |
| Jun 2025 | 11,786,000 | 11,101,000 | -15,060,000 | -14,660,000 | 89,138,000 | 34,905,000 | 46,349,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-78,718,000
Investing CF
$-737,000
Financing CF
$215,522,000
CapEx
$-886,000
Dividends Paid
—
Buybacks
$-231,000
EPS Diluted TTM
$-0.45
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-995,883,000
Inventory
$262,000
Receivables
$12,209,000
ST Investments
—
EBIT TTM
$-81,774,000
Pretax Income TTM
$-77,600,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$55,866,000
EBITDA
$-81,157,000
Free Cash Flow
$-50,099,752
Enterprise Value
$51,320,740
Total Cash
$184,152,992
Total Debt
$8,626,000
Shares Out
294,607,452
Trailing EPS
$-0.29
Book Value
$0.72
ROE
-60.3%
ROA
-29.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 53,426,000 | -55,560,000 | -52,489,000 | 276,883,000 | 35,343,000 | — | -58,135,000 |
| Dec 2024 | 25,384,000 | -176,876,000 | -169,925,000 | 129,515,000 | 61,976,000 | — | -170,491,000 |
| Dec 2023 | 0 | -207,783,000 | -198,643,000 | 229,181,000 | 51,713,000 | — | -173,164,000 |
| Dec 2022 | 0 | -226,258,000 | -241,317,000 | 383,167,000 | 27,197,000 | — | -219,987,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Max Pain — expiry 2026-12-18
max pain strike: $0.50 · spot: $0.87 · call oi: 4,469 · put oi: 314
Expected Move to 2026-12-18:
±$1.00
(115.13%) —
implied range
$-0.13 –
$1.87
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLLS | Cellectis S.A. | $224.37M | $3.09 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $231.68M | $2.50 | — |
| IKT | Inhibikase Therapeutics, Inc. | $220.49M | $1.67 | — |
| TARA | Protara Therapeutics, Inc. | $219.20M | $3.90 | — |
| CHRS | Coherus Oncology, Inc. | $215.95M | $1.40 | — |
News headlines (Yahoo Finance, 1h cache)
Invivyd doses first participants in Phase 3 COVID-19 trial
2026-06-09 16:22 · Yahoo
Invivyd Doses First Participants in Phase 3 Trial of COVID-19 Antibody VYD2311
2026-06-09 12:15 · Yahoo
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and
2026-06-09 11:01 · Yahoo
This Invivyd Insider Increased Their Holding In The Last Year
2026-06-06 13:11 · Yahoo
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-03 11:01 · Yahoo
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
2026-06-01 11:01 · Yahoo
Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now
2026-05-18 04:49 · Yahoo
Invivyd Inc (IVVD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments
2026-05-14 23:01 · Yahoo
Invivyd Q1 Earnings Call Highlights
2026-05-14 16:15 · Yahoo
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
2026-05-14 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.